Test Bank for Lehne’s Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants 3rd Edition by Rosenthal and Burchum

Prescribing is a privilege built on mastery, and the responsibility never ends.

Every prescription you write as a nurse practitioner or physician assistant is a consequential clinical decision. You are predicting how a specific drug will behave in a specific body, weighing its benefits against its risks, and accounting for renal function, hepatic metabolism, genetic variation, and the rest of the patient’s regimen. The right drug for one patient can be dangerous for another.

Advanced practice pharmacotherapeutics is not about knowing which drugs exist. It is about choosing the right drug, at the right dose, for this patient in this clinical context.

This test bank accompanies the 3rd Edition of Lehne’s Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants by Rosenthal and Burchum. It gives you focused, mechanism-driven, prescribing-level practice for every chapter. Use it for graduate course exams, clinical practicum assessments, or AANP, ANCC, and NCCPA certification preparation.

What’s Inside

• Hundreds of practice questions organized chapter by chapter
• Multiple-choice, select-all-that-apply, and complex clinical scenario formats
• Complete answer keys with evidence-based rationales
• Alignment with AANP, ANCC FNP-BC, and NCCPA exam standards
• Coverage from foundational prescribing principles to complex drug therapy management across all body systems

Who It’s For

• Family NP and Adult-Gerontology NP students
• PA students in pharmacotherapeutics coursework and clinical rotations
• AANP-C and ANCC FNP-BC candidates
• PANCE and PANRE candidates
• DNP students in advanced pharmacotherapy courses
• Nursing and PA faculty writing graduate-level exams
• Practicing NPs and PAs preparing for recertification
• Anyone whose program uses Rosenthal and Burchum, 3rd Edition

Table of Contents

UNIT I Introduction

1. Prescriptive Authority
2. Rational Drug Selection and Prescription Writing
3. Promoting Positive Outcomes of Drug Therapy

UNIT II Basic Principles of Pharmacology
4. Pharmacokinetics, Pharmacodynamics, and Drug Interactions
5. Adverse Drug Reactions and Medication Errors
6. Individual Variation in Drug Responses
7. Genetic and Genomic Considerations in Pharmacotherapeutics

UNIT III Drug Therapy Across the Life Span
8. Drug Therapy During Pregnancy and Breastfeeding
9. Drug Therapy in Pediatric Patients
10. Drug Therapy in Geriatric Patients

UNIT IV Peripheral Nervous System Drugs
11. Basic Principles of Neuropharmacology
12. Physiology of the Peripheral Nervous System
13. Muscarinic Agonists and Cholinesterase Inhibitors
14. Muscarinic Antagonists
15. Adrenergic Agonists
16. Adrenergic Antagonists
17. Indirect-Acting Antiadrenergic Agents

UNIT V Central Nervous System Drugs
18. Introduction to Central Nervous System Pharmacology
19. Drugs for Parkinson Disease
20. Drugs for Alzheimer Disease
21. Drugs for Seizure Disorders
22. Drugs for Muscle Spasm and Spasticity

UNIT VI Drugs for Pain
23. Local Anesthetics
24. Opioid Analgesics, Opioid Antagonists, and Nonopioid Centrally Acting Analgesics
25. Drugs for Headache

UNIT VII Psychotherapeutic Drugs
26. Antipsychotic Agents and Their Use in Schizophrenia
27. Antidepressants
28. Drugs for Bipolar Disorder
29. Sedative-Hypnotic Drugs
30. Management of Anxiety Disorders
31. Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder

UNIT VIII Substance Use Disorders
32. Substance Use Disorders I: Basic Considerations
33. Substance Use Disorders II: Alcohol
34. Substance Use Disorders III: Nicotine and Smoking
35. Substance Use Disorders IV: Major Drugs of Misuse Other Than Alcohol and Nicotine

UNIT IX Drugs That Affect the Heart, Blood Vessels, Blood, and Blood Volume
36. Review of Hemodynamics
37. Diuretics
38. Drugs Acting on the Renin-Angiotensin-Aldosterone System
39. Calcium Channel Blockers
40. Vasodilators
41. Drugs for Hypertension
42. Drugs for Heart Failure
43. Antidysrhythmic Drugs
44. Prophylaxis of Atherosclerotic Cardiovascular Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels
45. Drugs for Angina Pectoris
46. Anticoagulant and Antiplatelet Drugs
47. Drugs for Deficiency Anemias

UNIT X Drugs for Endocrine Disorders
48. Drugs for Diabetes
49. Drugs for Thyroid Disorders

UNIT XI Reproductive Health
50. Estrogens and Progestins: Basic Pharmacology and Noncontraceptive Applications
51. Birth Control
52. Androgens
53. Drugs for Benign Prostatic Hyperplasia
54. Drugs for Sexual Dysfunction
55. Transgender Health

UNIT XII Antiinflammatory, Antiallergic, and Immunologic Drugs
56. Review of the Immune System
57. Childhood Immunization
58. Antihistamines
59. Cyclooxygenase Inhibitors, Nonsteroidal Antiinflammatory Drugs, and Acetaminophen
60. Glucocorticoids in Nonendocrine Disorders

UNIT XIII Drugs for Bone and Joint Disorders
61. Drug Therapy for Rheumatoid Arthritis
62. Drug Therapy for Gout
63. Drugs Affecting Calcium Levels and Bone Mineralization

UNIT XIV Respiratory Tract Drugs
64. Drugs for Asthma and Chronic Obstructive Pulmonary Disease
65. Drugs for Allergic Rhinitis, Cough, and Colds

UNIT XV Gastrointestinal Drugs
66. Drugs for Peptic Ulcer Disease
67. Laxatives
68. Other Gastrointestinal Drugs

UNIT XVI Nutrition and Complementary Therapies
69. Vitamins
70. Drugs for Obesity
71. Complementary and Alternative Therapy

UNIT XVII Therapy for Infectious and Parasitic Diseases
72. Basic Principles of Antimicrobial Therapy
73. Drugs That Weaken the Bacterial Cell Wall I: Penicillins
74. Drugs That Weaken the Bacterial Cell Wall II: Other Drugs
75. Bacteriostatic Inhibitors of Protein Synthesis
76. Aminoglycosides: Bactericidal Inhibitors of Protein Synthesis
77. Sulfonamide Antibiotics and Trimethoprim
78. Drug Therapy for Urinary Tract Infections
79. Drug Therapy for Tuberculosis
80. Miscellaneous Antibacterial Drugs
81. Antifungal Agents
82. Antiviral Agents I: Drugs for Non-HIV Viral Infections
83. Antiviral Agents II: Drugs for HIV Infection
84. Drug Therapy for Sexually Transmitted Infections
85. Anthelmintics

UNIT XVIII Cancer Therapy
86. Introduction to Immunomodulators
87. Supportive Care of Patients Receiving Anticancer Drugs
88. Drugs for Cancer Pain

UNIT XIX Drugs for Eyes, Ears, and Skin
89. Drugs for Disorders of the Eye
90. Drugs for Disorders of the Skin
91. Drugs for Disorders of the Ear

UNIT XX Drug Therapy in Acute Care
92. Agents Affecting the Volume and Ion Content of Body Fluids
93. Management of ST-Elevation Myocardial Infarction
94. Drugs for Acute Care

Why This Test Bank Stands Out

Rosenthal and Burchum’s text sets the standard for advanced practice pharmacotherapy because it teaches at the depth and specificity that prescribers need, which undergraduate pharmacology resources don’t reach. The 3rd Edition is its most thorough update yet, with new FDA approvals and safety communications, revised guidelines across every therapeutic area, and expanded coverage of SGLT-2 inhibitors, GLP-1 receptor agonists, biologics, and direct oral anticoagulants.

This test bank matches that level. Its questions ask you to:

• Select the best first-line therapy for a patient with specific comorbidities, using current guidelines.
• Spot a dangerous drug interaction before it reaches the patient, then decide whether to adjust the dose, intensify monitoring, or substitute the drug.
• Apply the Beers Criteria and STOPP guidelines to a geriatric patient’s regimen and recommend safer alternatives.
• Adjust doses for renally impaired patients taking antibiotics with narrow therapeutic windows.

Each rationale walks through the mechanism, the guideline, the patient-specific reasoning, and the monitoring plan behind the answer.

Sample Questions

Question 1
A nurse practitioner is managing a 58-year-old with type 2 diabetes, a myocardial infarction two years ago, and an eGFR of 55 mL/min/1.73 m². He takes metformin 1000 mg twice daily and atorvastatin 40 mg daily. His HbA1c is 8.3% and his blood pressure is 136/84 mmHg. Which addition best reflects current ADA Standards of Care?

A) A sulfonylurea such as glipizide, for effective glucose lowering with long-term safety data
B) A GLP-1 receptor agonist such as semaglutide or liraglutide, which reduce cardiovascular events in established CVD independent of glycemic effect
C) Basal insulin glargine, since an HbA1c above 8% always requires insulin
D) Sitagliptin, a DPP-4 inhibitor, as a neutral agent with proven cardiovascular safety

Correct answer: B
Rationale: For type 2 diabetes with established atherosclerotic cardiovascular disease, the ADA recommends a GLP-1 receptor agonist or an SGLT-2 inhibitor with proven cardiovascular benefit, regardless of baseline HbA1c. Liraglutide (LEADER), semaglutide (SUSTAIN-6), and dulaglutide (REWIND) reduced major adverse cardiovascular events, and the benefit does not depend on glucose lowering. Sulfonylureas add hypoglycemia risk without cardiovascular benefit. Insulin is not mandatory at an HbA1c above 8% when better agents remain unused. DPP-4 inhibitors show cardiovascular safety, not benefit. With an eGFR of 55, an SGLT-2 inhibitor with renal benefit is also a reasonable choice.

Question 2
A physician assistant is reviewing medications for a 45-year-old taking phenelzine for treatment-resistant depression. The patient has severe nasal congestion and asks about over-the-counter pseudoephedrine. What is the most accurate response?

A) It is safe because over-the-counter products cannot interact seriously with prescription antidepressants
B) It is contraindicated because combining a sympathomimetic with an MAOI risks a hypertensive crisis; recommend saline irrigation and intranasal corticosteroids instead
C) It can be used at half the usual dose with blood pressure monitoring
D) The interaction is only theoretical, with no documented clinical cases

Correct answer: B
Rationale: MAOIs block the breakdown of catecholamines in adrenergic nerve terminals. Pseudoephedrine triggers norepinephrine release and blocks its reuptake. With the MAOI in place, the released norepinephrine cannot be metabolized and floods the synapse. The result can be a severe hypertensive crisis with encephalopathy, intracranial hemorrhage, or death. No dose is reliably safe, and the warning covers all indirect-acting sympathomimetics. Saline irrigation, intranasal corticosteroids, and antihistamines without a decongestant component are safe alternatives.

Question 3
A family nurse practitioner is caring for a 32-year-old woman whose epilepsy is well controlled on valproic acid. She has just learned she is eight weeks pregnant and wants to stop the drug immediately. What is the best counseling?

A) Stop it now, because any anticonvulsant harms the fetus and months without seizures show she no longer needs it
B) Arrange urgent consultation with neurology and obstetrics; valproate carries significant teratogenic risk, so a switch to a safer agent is strongly preferred, but abrupt discontinuation risks breakthrough seizures that endanger both mother and fetus
C) Reassure her that valproate is completely safe in pregnancy
D) Switch to carbamazepine immediately, since it has no teratogenic risk

Correct answer: B
Rationale: Valproate has the highest teratogenic risk among commonly used anticonvulsants. It is linked to neural tube defects, cardiac and craniofacial malformations, fetal valproate syndrome, and later neurodevelopmental problems such as lower IQ, autism spectrum disorder, and ADHD. FDA, EMA, and ACOG guidance advises avoiding it in pregnancy when an effective alternative exists. Abrupt withdrawal is also dangerous, because generalized tonic-clonic seizures can cause trauma, hypoxia, and placental abruption, and status epilepticus is life-threatening. The right approach is a supervised transition, often to lamotrigine or levetiracetam, with close maternal and fetal monitoring. Carbamazepine also carries neural tube defect risk, and no anticonvulsant is risk-free in pregnancy.

Question 4
A nurse practitioner is managing a 68-year-old man with atrial fibrillation and a CHA₂DS₂-VASc score of 4. He has had stable, therapeutic INRs on warfarin for three years. His daughter has read that “newer blood thinners” are better, and he asks to switch to rivaroxaban. What is the best response?

A) Switch immediately, since DOACs are always superior to warfarin
B) Hold a shared decision-making discussion: DOACs are non-inferior or superior for stroke prevention, with favorable bleeding profiles and no INR monitoring, but a stable patient needs individualized review of renal function, adherence, cost, and preference
C) Decline, since warfarin is the only guideline-recommended anticoagulant for AF
D) Switch only if the INR has been unstable; stable patients should always stay on warfarin

Correct answer: B
Rationale: ARISTOTLE, ROCKET-AF, RE-LY, and ENGAGE AF-TIMI 48 showed that DOACs prevent stroke at least as well as warfarin in non-valvular AF, with generally comparable or better bleeding outcomes and fixed dosing. ACC/AHA guidelines prefer DOACs for most patients with non-valvular AF, including those transitioning from warfarin. A patient who is stable on warfarin still warrants individualized review rather than automatic switching or reflexive refusal. Rivaroxaban needs dose adjustment at lower renal function and is contraindicated below a CrCl of 15 mL/min. DOACs also require consistent adherence with no monitoring to catch missed doses, and they cost considerably more.

Question 5
A physician assistant is treating a 55-year-old with left lower lobe pneumonia caused by Streptococcus pneumoniae. The isolate is penicillin-susceptible and azithromycin-resistant. The chart lists a penicillin allergy as “rash as a child, nature unknown.” Which decision best reflects antimicrobial stewardship and allergy assessment principles?

A) Prescribe azithromycin as the standard macrolide for community-acquired pneumonia
B) Prescribe levofloxacin to avoid beta-lactams given the documented allergy
C) Perform a structured penicillin allergy assessment; if the risk is low, proceed to skin testing or a graded amoxicillin challenge and use amoxicillin if tolerated, and if avoidance is required, choose doxycycline or a respiratory fluoroquinolone based on susceptibility
D) Prescribe cephalexin, since all cephalosporins are completely safe in penicillin allergy and equivalent for this organism

Correct answer: C
Rationale: About 10% of patients report a penicillin allergy, yet fewer than 1% have a confirmed IgE-mediated allergy. Many reports reflect side effects, viral rashes blamed on the antibiotic, or sensitivity that faded over time. A childhood rash of unknown character is a low-specificity history that deserves assessment before lifelong avoidance. Delabeling restores access to amoxicillin, the preferred narrow-spectrum agent for penicillin-susceptible pneumococcal pneumonia. Using a fluoroquinolone on the basis of an unvalidated label adds resistance pressure, adverse effects, and cost. Azithromycin is inappropriate because the isolate is resistant, whatever the allergy history.

Frequently Asked Questions

Which edition does this test bank cover?
The 3rd Edition of Lehne’s Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants by Rosenthal and Burchum. Questions follow that edition’s chapter organization, updated guidelines, and current FDA safety communications.

Does it follow the textbook’s structure?
Yes. Questions are organized by unit and chapter, from Unit I (Introduction) through Unit XX (Drug Therapy in Acute Care), covering all 94 chapters. You can work through the book in order or target the units your exam covers.

Is it aligned with NP and PA certification exams?
Yes. The questions reflect the pharmacology and prescribing-level reasoning tested on the AANP-C, ANCC FNP-BC, PANCE, and PANRE, including drug selection, interaction management, guideline-based prescribing, and patient-specific decisions.

Is it useful for both NP and PA students?
Yes. The textbook is used in both graduate nursing and PA programs, and the scenarios reflect the prescribing decisions both professions face.

How soon can I access it?
Immediately. You get instant digital access after purchase and can study on any device, on your own schedule.

Are the rationales based on current evidence?
Yes. They draw on current ADA Standards of Care, ACC/AHA cardiovascular guidelines, IDSA protocols, the AGS Beers Criteria, FDA prescribing standards, and antimicrobial stewardship principles, consistent with the framework Rosenthal and Burchum use throughout the 3rd Edition.

Can faculty use it for course assessments?
Yes. The unit-by-unit organization, scenario-based format, and graduate-level difficulty suit quizzes, unit exams, and comprehensive assessments in NP and PA pharmacotherapeutics courses.